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Abstract: Acute osteomyelitis and septic arthritis are two infections whose frequencies are increasing
in pediatric patients. Acute osteomyelitis and septic arthritis need to be carefully assessed, diagnosed,
and treated to avoid devastating sequelae. Traditionally, the treatment of acute osteoarticular infection
in pediatrics was based on prolonged intravenous anti-infective therapy. However, results from
clinical trials have suggested that in uncomplicated cases, a short course of a few days of parenteral
antibiotics followed by oral therapy is safe and effective. The aim of this review is to provide
clinicians an update on recent controversies and advances regarding the management of acute
osteomyelitis and septic arthritis in children. In recent years, the emergence of bacterial species
resistant to commonly used antibiotics that are particularly aggressive highlights the necessity for
further research to optimize treatment approaches and to develop new molecules able to fight the
war against acute osteoarticular infection in pediatric patients.
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1. Introduction
Acute osteomyelitis and septic arthritis represent two inflammatory diseases that affect bone and
synovial joints and are both primarily caused by bacterial infection [1–3]. These two diseases can occur
alone or in combination. Traditionally, their incidence is approximately eight cases per 100,000 children
per year, with high prevalence in those aged ď5 years. However, in recent years, an increase in their
incidence has been observed. There is a higher incidence in males, most likely because they are more
physically active, which predisposes them to repeated microtrauma [1–3]. Hips, knees, and ankles are
the most frequently involved joints [4–6].
The pathogenesis of acute osteomyelitis and septic arthritis may occur with three different
mechanisms: the pathogen’s dissemination via the blood, extension by contiguity, or penetration of
the infectious agent [6]. The first mechanism is the most frequently described in children.
Acute osteomyelitis and septic arthritis, although not so frequent, should not be underestimated
because they could be associated with sepsis and with sequelae such as joint destruction, growth failure,
and death of the patient if they are not correctly treated [7,8]. Therefore, early diagnosis and initiation
of proper treatment are essential to obtain a better outcome and avoid sequelae. Furthermore, the
emergence of bacterial strains particularly virulent and resistant to antibiotics has made the treatment
of these conditions more difficult than in the past and has led to the need to have new antibiotic
molecules available to deal with these emergencies [7,9]. However, there is no consensus in the
literature regarding the best antibiotic therapy to be administered, the mode of administration, and the
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duration of therapy. These topics are still the subject of an ongoing debate among experts. The aim
of this review is to provide clinicians an update on recent controversies and advances regarding the
management of acute osteomyelitis and septic arthritis in children.
2. Controversies in Management
Antibiotic therapy is the gold standard for treating acute osteomyelitis and septic arthritis.
The antibiotic is initially chosen on an empirical basis to cover the most frequent pathogens responsible
for these conditions based on the age of the child and is then driven on the basis of the antibiograms
obtained from the cultural investigations performed before starting antimicrobial therapy (such as
blood culture or, when available, intra-articular liquid or bone fragment) [10]. However, there is an
urgent need for treating all the infants and children who are admitted with these diseases due to their
severe clinical conditions and risks of complications. Unfortunately, in several cases, the blood culture
is negative and the other invasive procedures, different from what is done in adults, are not performed
in the first years of life. Therefore, it is important to know the epidemiology reported in the literature
for different age groups to help choose an appropriate empirical treatment.
Staphylococcus aureus is definitely the most frequent pathogen responsible for osteomyelitis and
septic arthritis in any age group, mainly methicillin-sensitive strains (MSSA), and it is responsible
for up to 70%–90% of confirmed cases [11]. As noted in the adult population, there has also been an
increase in cases of osteoarticular infection due to methicillin-resistant strains of S. aureus (MRSA) in
pediatric patients that should consequently be considered when choosing an empirical antimicrobial
treatment [7,12].
In children less than two months of age, Streptococcus agalactiae and other Gram-negative organisms
are recognized as potential pathogens. However, in children between two and five years of age,
Streptococcus pyogenes and Streptococcus pneumoniae should be considered [13]. Haemophilus influenzae
type b was considered a common cause of acute osteoarticular infections in children [14]. Fortunately,
after the introduction of large-scale vaccination programs, the number of cases of acute osteomyelitis
and septic arthritis due to H. influenzae type b has drastically decreased.
An emerging pathogen in the etiology of pediatric acute osteoarticular infection is Kingella kingae.
It is a common commensal of the oropharynx of children that affects children between six months and
four years of life in particular, and it is difficult to isolate [15]. Using aerobic blood culture vials or
real-time polymerase chain reaction (PCR), the bacterium can be more easily identified. Some authors
showed that K. kingae appeared as the most frequent etiologic agent of acute osteoarticular infections
in children aged less than four years, excluding the neonatal period [16,17].
Rare causes of osteomyelitis in pediatric patients are Mycobacterium tuberculosis, Bartonella henselae,
and fungi (i.e., Histoplasma spp. and Cryptococcus spp.) [4–6]. These pathogens should be considered
mainly in immunocompromised children.
Given the distribution of pathogens in the different age groups, in neonates, empirical treatment
should include oxacillin with the addition of gentamicin [18,19]. In children older than three months,
to cover MSSA, S. pyogenes, and K. kingae, antistaphylococcal penicillin such as nafcillin or oxacillin
or a first-generation cephalosporin such as cefazolin should be used [18]. However, in the case
of a high suspicion of MRSA infection (i.e., countries with a prevalence of MRSA ě10%, patients
previously hospitalized in the intensive care unit, immunocompromised patients), antibiotic coverage
against this pathogen should be recommended. In these cases, a first choice may be the use of
clindamycin, an antibiotic belonging to the class of lincosamides, the effectiveness of which has been
shown [20]. If the percentage of local resistance to clindamycin is greater than 10%, the drug of
first choice is vancomycin [21,22]. However, this glycopeptide has the disadvantage of requiring
intravenous administration and therapeutic drug monitoring for possible toxic effects. In cases of
MRSA that are unresponsive to clindamycin and vancomycin, an alternative option is linezolid [8,11,23].
Linezolid belongs to the class of oxazolidinones, and it is effective against infections caused by
Gram-positive bacteria, such as MRSA, coagulase-negative staphylococci, glycopeptide-resistant
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enterococci, and penicillin-resistant Streptococcus pneumoniae. Linezolid also has the advantage of
having very good absorption even orally. Additionally, various studies have established the required
dosages in neonatal and pediatric patients; however, it is expensive and, in cases of protracted
therapies, may be associated with the development of hematological abnormalities as well as optical
and peripheral neuropathies [19,24].
Even daptomycin, a lipopeptide antibiotic, may be considered a useful antibiotic in the case of
multi-resistant Gram-positive bacteria. However, further studies in neonatal and pediatric patients are
required to validate the use of this antibiotic in children [25].
Trimethoprim-sulfamethoxazol has been successfully used for the treatment of skin and soft tissue
infections due to MRSA [26]. A small retrospective study by Messina et al. showed that in the case of
pediatric osteomyelitis due to MRSA, trimethoprim-sulfamethoxazol represents an effective treatment
option [27]. However, larger clinical trials are needed to confirm this therapeutic choice [28].
In recent years, acute osteoarticular infections due to S. aureus strains producing Panton-Valentine
leukocidin have been reported, although not so frequently in Europe [29–33]. Panton-Valentine
leukocidin (PVL) is a toxin that causes tissue necrosis and destruction of the neutrophils, thereby
facilitating the extension of the infection, and children affected by this pathogen have more
aggressive clinical features [21,22,30,34–36]. The risk of complications such as subperiosteal abscesses,
pyomyositis, necrotizing fasciitis, and orthopedic sequelae is high [37]. Therefore, cases of bone or
joint infection caused by S. aureus strains producing PVL require more aggressive and prolonged
antimicrobial treatment and often require repeated surgical debridement [32,38]. The use of fluoxacillin,
clindamycin or linezolid is recommended in these cases, with daptomycin considered as a second-line
antibiotic. Daptomycin was successfully used in a recent case report of a child with PVL-positive
staphylococcal osteomyelitis [39].
Salmonella spp. is a frequent cause of acute osteoarticular infection in developing countries and in
patients with sickle cell disease [40–42]. For this type of infection, a third-generation cephalosporin
such as cefotaxime or ceftriaxone or a fluoroquinolone should be considered [43].
Finally, Candida spp. is another pathogen that may be identified from some cases of acute
osteomyelitis (mainly spondylodiscitis) which requires a prolonged antifungal treatment and surgical
debridement [44].
However, the identification of the pathogen responsible for the acute osteoarticular infection
requires time due to the slow growth of some etiologic agents. Moreover, invasive procedures that
require the patient’s sedation are limited in pediatric patients for ethical reasons. According to various
studies, it seems possible in anywhere from 30% to 70% of cases, and the severity of the clinical picture
as well as the patient’s age are key aspects for the selection of antibiotic therapy [22].
3. The Duration of Anti-Infective Treatment
Acute osteomyelitis and septic arthritis require prompt anti-infective treatment, starting with
intravenous antibiotics and then transitioning to oral antibiotics to avoid complications. However,
there is an absence of consensus regarding antibiotic duration and when to change to oral treatment.
Traditionally, children with acute osteomyelitis and septic arthritis receive intravenous antibiotic
therapy for several weeks, then switch to oral therapy when healing has almost been achieved [43].
However, the long duration of parenteral therapy was associated with prolonged hospitalization, high
cost, and sometimes the need for central venous access. Some centers start the peripheral intravenous
therapy for some days during hospitalization and then insert a central venous catheter to provide four
to six weeks of parenteral therapy at home [45].
Some authors have suggested the possibility of reducing the duration of intravenous antibiotic
therapy to only a few days and then continuing the therapy orally [3,33,46–52]. In a prospective
randomized study performed by Peltola et al., pediatric patients with acute osteomyelitis caused primarily
by MSSA strains treated with oral antibiotics (clindamycin or a first-generation cephalosporin) for 20 days
attained the same efficacy as patients treated for 30 days after an initial intravenous treatment of two to
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four days in both groups [48]. Similar results were obtained by Jagodzinski et al. in 70 children between
two weeks and 14 years of age suffering from acute osteomyelitis or septic arthritis who were treated
for three to five days with intravenous therapy at high doses and then later with an oral therapy for
three weeks [49]. However, in the case of MRSA or PVL S. aureus, four to six weeks of treatment are
recommended [23].
Also, it was demonstrated that two to three weeks of large doses of well-absorbed antibiotics
started intravenously and only one joint aspiration appear to be sufficient for the treatment of septic
arthritis in children [53]. The oral administration of antibiotics exposes the patient to a lower risk of
complications associated with prolonged antibiotic parenteral administration at home and results in
fewer visits to the emergency department and lower rehospitalization rates [54,55].
Undoubtedly, the child should not present severe complications, must be able to assume the
antibiotic therapy orally, and should tolerate the drug; the antibiotic should also have high oral
bioavailability and reach adequate concentrations at the site of the infection [8]. Finally, the oral
antibiotic must have the same degree of antibacterial coverage as the parenteral drug [19].
The transition from intravenous antibiotic therapy to oral therapy can also be guided by other
factors. In particular, an improvement in the general condition of the child, stable apyrexia, and a
significant reduction in C-reactive protein (CRP) should be present. Recently, Chou et al. observed
that a 50% reduction in CRP associated with a clinical improvement of the patient can be used for the
transition to oral antimicrobial therapy in acute bacterial osteoarticular infection [56]. Similar results
were obtained in a retrospective study by Pääkkönen et al. in which patients affected by uncomplicated
osteomyelitis of the calcaneus not caused by MRSA were analyzed [57]. Arnold et al. [58] showed 99.5%
success in 194 pediatric patients with acute bacterial osteomyelitis who were switched to oral therapy
as a result of an improvement of the clinical picture and CRP < 2 mg/dL. Only one patient experienced
treatment failure, but this was due to a retained infected bone fragment in the hip joint [58]. Finally, a
CRP value of less than 2 mg/dL appeared to be a useful indicator for suspending antibiotic therapy in
acute bacterial osteoarticular infection [58].
However, complicated cases of acute osteoarticular infections, including those that occur at
neonatal age or in immunocompromised children as well as cases due to Salmonella spp. or MRSA,
require longer treatment [50,59]. Interestingly, Jagodzinski et al. demonstrated that initial CRP levels
higher than 10 mg/dL and a temperature above 38.4 ˝C should be considered predictors of the need
for a prolonged course of intravenous antibiotic administration [49]. In cases where the values of CRP
are persistently elevated despite antibiotic therapy, a complication should be suspected and antibiotic
therapy should be modified or prolonged [19].
In conclusion, a short course of intravenous antibiotic treatment followed by an oral antimicrobial
therapy for two to three weeks in septic arthritis and three weeks in osteomyelitis appears to be safe
and effective in cases of uncomplicated osteoarticular infection. In the other cases, intravenous therapy
should be prolonged for at least three weeks in septic arthritis and four to six weeks in osteomyelitis.
However, the duration of anti-infective treatment should always rely on clinical judgment, objective
diagnostic data, and oral bioavailability of the different antibiotics.
4. Other Drugs
In the case of septic arthritis, two clinical trials studied the effects of dexamethasone on antibiotic
therapy. In both of these double-blind, placebo-controlled studies, it was observed that four days
of intravenous dexamethasone together with antibiotic therapy resulted in a shorter duration of
symptomatology as well as a minor residual dysfunction of the joint at the end of antibiotic therapy
and during follow-up [60,61].
These results were recently confirmed in a large retrospective study by Fogel et al. [62] who
analyzed 116 pediatric patients with septic arthritis, 90 of whom were treated with antibiotics alone
and 26 of whom were treated with antibiotics in addition to intravenous dexamethasone for a few days.
The latter group experienced a shorter duration of fever (mean 2.3 vs. 3.9 days, p = 0.002), a more rapid
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clinical improvement (mean 6.3 vs. 10.0 days to no pain/limitation, p < 0.001), a more rapid decrease
in CRP levels to <1 mg/dL (mean 5.3 vs. 8.4 days, p = 0.002), a shorter duration of parenteral antibiotic
treatment (mean 7.1 vs. 11.4 days, p < 0.001), and a shorter hospital stay (mean 8.0 vs. 10.7 days,
p = 0.004) [62].
However, although these studies suggest that treatment with corticosteroids is associated with a
better outcome, more studies are needed to confirm these results [63].
Non-steroidal anti-inflammatory agents (NSAIDs) should be used to reduce pain [1].
Furthermore, in adult patients with orthopedic implants it has been shown that biofilm may
cause failure of antibiotic treatment [64,65]. In vitro findings have suggested that local delivery of
antimicrobials may be an effective strategy for the prevention and/or treatment of open fractures
where biofilms might develop [66,67].
5. Surgery
Together with antibiotics, surgery plays a key role in the treatment of acute osteomyelitis and
septic arthritis in children [3].
First, surgery makes it possible to obtain biological samples that are useful for identifying the
etiologic agent and then guiding the selection of the correct antibiotic to use for treatment. Moreover,
in cases with joint involvement, surgical drainage of the joint reduces the risk of complications such
as avascular necrosis of the bone and permanent cartilage damage due to increased intra-articular
pressure and results in a better outcome [50]. Furthermore, arthroscopic lavage was found to be safe
and effective for the treatment of septic arthritis in very young children [68]. In addition, surgery
alters the process of bone necrosis, which reduces the vasculature and therefore the penetration of the
antibiotic at the site of infection, removes the demineralized bone, and cleans the surrounding soft
tissue, thereby reducing the bacterial load [38].
However, in acute uncomplicated cases of osteoarticular infection, surgery may not be
necessary [22]. It should be considered in patients who do not respond to antibiotic treatment for
the suspicion of an underlying complication. Acute osteoarticular infections caused by MRSA or
S. aureus producing PVL often require more surgical sessions as these bacteria are associated with a
more aggressive clinical course [50].
6. Conclusions
Acute osteomyelitis and septic arthritis are two infections whose frequencies are increasing in
pediatric patients. Acute osteomyelitis and septic arthritis need to be carefully assessed, diagnosed,
and treated to avoid devastating sequelae.
It is currently accepted that initial treatment of acute osteomyelitis and septic arthritis involves
empirical antibiotic therapy that should cover the pathogens potentially responsible for these infections
based on age groups. However, there is no consensus on which molecule(s) should be used in various
countries. This lack of consensus is mostly due to the different antibiotic-resistant microorganisms
in the different regions of the world. Consequently, the choice of antibiotic should be individualized
to cover the microbial profiles of the different regions, as well as considering the patient’s age and
clinical status.
In cases of acute uncomplicated osteomyelitis and septic arthritis, antibiotic treatment can be
provided intravenously for a short period of a few days and then orally until the end of the disease.
The improvement in the clinical status and the inflammatory markers can be used by clinicians to
decide on the timing of the switch to oral therapy. The latter should only be administered if the patient
is capable of taking it adequately and only if it has the same spectrum of coverage as the antibiotic
used parenterally.
In the last few years, the emergence of bacterial strains particularly virulent and resistant to
antibiotics has been observed. These pathogens are associated with highly aggressive and dangerous
clinical features. Consequently, in these cases, as well as in the neonates and in patients with chronic
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underlying disease, it is extremely important to obtain as much reliable sample as possible for
microbiological examination and to start a prompt, aggressive, prolonged intravenous treatment.
However, several gaps in the management of acute osteoarticular infections remain. There are
relatively few studies of the diagnostic methods that should be performed for the identification of
the different pathogens and the most appropriate parameters to be used in children to switch from
parenteral to oral antibiotic therapy in relation to the etiology. Consequently, further research should
focus on these issues to optimize the duration of intravenous and oral anti-infectives. Moreover, further
studies of the quantitative impact of MRSA and S. aureus PVL-producing strains in these infections
as well as on the optimal treatment in terms of the molecule of choice and the duration of antibiotic
administration are mandatory. In addition, limited data on the efficacy and safety of corticosteroids in
patients with acute osteoarticular infection are available, and further studies on this issue should be
useful. Furthermore, the role of biofilm in treatment failures in pediatric patients should be evaluated.
Finally, the emergence of bacterial strains resistant to antibiotics makes it imperative to focus the
research on the search for new molecules that are capable of adequately penetrating bones and joints
to overcome this problem.
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